BioNTech SE ADR [BNTX] stock prices are up 0.47% to $118.77 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BNTX shares have gain 5.06% over the last week, with a monthly amount glided 35.58%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
BioNTech SE ADR [NASDAQ: BNTX] stock has seen the most recent analyst activity on September 24, 2024, when Morgan Stanley upgraded its rating to a Overweight and also boosted its price target to $145 from $93. Previously, Jefferies upgraded its rating to Buy on September 17, 2024, and elevated its price target to $150. On September 16, 2024, upgrade upgraded it’s rating to Neutral and revised its price target to $125 on the stock. Deutsche Bank upgraded its rating to a Buy but stick to its price target of $95 on August 07, 2024. HSBC Securities upgraded its rating to a Buy. Evercore ISI started tracking with a In-line rating for this stock on May 14, 2024, and assigned it a price target of $100. In a note dated February 23, 2024, BMO Capital Markets initiated an Outperform rating and provided a target price of $127 on this stock.
The stock price of BioNTech SE ADR [BNTX] has been fluctuating between $76.53 and $131.49 over the past year. Currently, Wall Street analysts expect the stock to reach $156.86 within the next 12 months. BioNTech SE ADR [NASDAQ: BNTX] shares were valued at $118.77 at the most recent close of the market. An investor can expect a potential return of 32.07% based on the average BNTX price forecast.
Analyzing the BNTX fundamentals
The BioNTech SE ADR [NASDAQ:BNTX] reported sales of 2.91B for trailing twelve months, representing a drop of -24.09%. Gross Profit Margin for this corporation currently stands at 0.64% with Operating Profit Margin at -0.23%, Pretax Profit Margin comes in at -0.09%, and Net Profit Margin reading is -0.19%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.03 and Total Capital is -0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 117.39 points at the first support level, and at 116.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 119.68, and for the 2nd resistance point, it is at 120.58.
Ratios To Look Out For
It’s worth pointing out that BioNTech SE ADR [NASDAQ:BNTX]’s Current Ratio is 7.54. In addition, the Quick Ratio stands at 7.40 and the Cash Ratio stands at 4.28. Considering the valuation of this stock, the price to sales ratio is 9.71, the price to book ratio is 1.38.
Transactions by insiders
Recent insider trading involved ATHOS KG, 10% Owner, that happened on Sep 30 ’24 when 76114.0 shares were purchased. 10% Owner, ATHOS KG completed a deal on Sep 27 ’24 to buy 37204.0 shares. Meanwhile, 10% Owner ATHOS KG bought 37943.0 shares on Sep 25 ’24.
